Molecular portrait of cisplatin induced response in human testis cancer cell lines based on gene expression profiles.
BACKGROUND
Testicular germ cell tumors (TGCTs) respond well to cisplatin-based chemotherapy and show a low incidence of acquired resistance compared to most somatic tumors. The reasons for these specific characteristics are not known in detail but seem to be multifactorial. We have studied gene expression profiles of testicular and colon cancer derived cell lines treated with cisplatin. The main goal of this study was to identify novel gene expression profiles with their functional categories and the biochemical pathways that are associated with TGCT cells' response to cisplatin.


RESULTS
Genes that were differentially expressed between the TGCT cell lines vs the (somatic) HCT116 cell line, after cisplatin treatment, were identified using the significance analysis of microarrays (SAM) method. The response of TGCT cells was strikingly different from that of HCT116, and we identified 1794 genes that were differentially expressed. Functional classification of these genes showed that they participate in a variety of different and widely distributed functional categories and biochemical pathways. Database mining showed significant association of genes (n = 41) induced by cisplatin in our study, and genes previously reported to by expressed in differentiated TGCT cells. We identified 37 p53-responsive genes that were altered after cisplatin exposure. We also identified 40 target genes for two microRNAs, hsa-mir-372 and 373 that may interfere with p53 signaling in TGCTs. The tumor suppressor genes NEO1 and LATS2, and the estrogen receptor gene ESR1, all have binding sites for p53 and hsa-mir-372/373. NEO1 and LATS2 were down-regulated in TGCT cells following cisplatin exposure, while ESR1 was up-regulated in TGCT cells. Cisplatin-induced genes associated with terminal growth arrest through senescence were identified, indicating associations which were not previously described for TGCT cells.


CONCLUSIONS
By linking our gene expression data to publicly available databases and literature, we provide a global pattern of cisplatin induced cellular response that is specific for testicular cancer cell lines. We have identified cisplatin-responsive functional classes and pathways, such as the angiogenesis, Wnt, integrin, and cadherin signaling pathways. The identification of differentially expressed genes in this study may contribute to a better understanding of the unusual sensitivity of TGCT to some DNA-damaging agents.
Duale
Nur
N
Department of Chemical Toxicology, Division of Environmental Medicine, Norwegian Institute of Public Health, Oslo, Norway. nur.duale@fhi.no
Lindeman
Birgitte
B
Komada
Mitsuko
M
Olsen
Ann-Karin
AK
Andreassen
Ashild
A
Soderlund
Erik J
EJ
Brunborg
Gunnar
G
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002945:Cisplatin / Q000627:therapeutic use*; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D013736:Testicular Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D002945:Cisplatin
Nat Genet. 2001 Dec;29(4):365-71
11726920
Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):389-94
11752408
Cancer Lett. 2002 May 8;179(1):1-14
11880176
J Clin Oncol. 2002 Mar 15;20(6):1551-61
11896104
J Biol Chem. 2002 Apr 26;277(17):14877-83
11836256
Drug Resist Updat. 2001 Oct;4(5):303-13
11991684
Cell. 2002 May 3;109(3):335-46
12015983
Bioinformatics. 2002 Aug;18(8):1135-6
12176838
J Inorg Biochem. 2002 Aug 30;91(3):451-62
12175937
Cancer Res. 2002 Nov 1;62(21):6255-62
12414655
J Cell Biochem. 2003 Jan 1;88(1):83-94
12461777
Chest Surg Clin N Am. 2002 Nov;12(4):695-706
12471872
Semin Cancer Biol. 2003 Feb;13(1):49-58
12507556
Neoplasia. 2005 Sep;7(9):816-23
16229804
Cell. 2006 Jan 13;124(1):207-19
16413492
Int J Cancer. 2006 Apr 1;118(7):1699-712
16217747
Cell. 2006 Mar 24;124(6):1169-81
16564011
Genome Biol. 2006;7(3):R25
16584535
Nucleic Acids Res. 2006 Jul 1;34(Web Server issue):W645-50
16912992
Oncogene. 2006 Oct 9;25(46):6188-96
17028598
Cell Death Differ. 2006 Nov;13(11):1927-37
16528385
BMC Bioinformatics. 2006;7:470
17062145
Cancer Lett. 2007 Mar 8;247(1):137-42
16697107
Oncogene. 2007 Apr 26;26(19):2717-26
17130844
Clin Cancer Res. 2003 Feb;9(2):767-73
12576448
Nucleic Acids Res. 2003 Feb 15;31(4):1351-63
12582255
Verh Dtsch Ges Pathol. 2002;86:67-75
12647353
Oncogene. 2003 May 8;22(18):2805-11
12743603
J Pathol. 2003 Jun;200(2):137-48
12754734
Ann Oncol. 2003 Jun;14(6):825-32
12796018
Nat Rev Cancer. 2003 Jul;3(7):517-25
12835671
Oncogene. 2003 Jul 10;22(28):4398-405
12853976
Nat Genet. 2003 Nov;35(3):215-7
14528307
Nucleic Acids Res. 2003 Dec 15;31(24):e154
14654707
Nucleic Acids Res. 2004 Jan 1;32(Database issue):D91-4
14681366
Cell. 2003 Dec 26;115(7):787-98
14697198
Int J Cancer. 2004 Jun 20;110(3):352-61
15095299
Oncogene. 2004 Jun 17;23(28):4862-72
15122333
Environ Health Perspect. 2004 Aug;112(12):1236-48
15345370
Lancet. 1972 Sep 9;2(7776):516-7
4115573
Cancer Res. 1980 Jul;40(7):2500-6
7388807
Int J Cancer. 1987 Sep 15;40(3):334-43
2442105
Cancer Res. 1996 Sep 1;56(17):4006-12
8752171
N Engl J Med. 1997 Jul 24;337(4):242-53
9227931
Biochemistry. 1998 Jan 6;37(1):352-62
9425057
Proc Natl Acad Sci U S A. 1998 May 26;95(11):6163-8
9600935
Br J Cancer. 1998 May;77(10):1562-7
9635829
Cancer Res. 1998 Nov 15;58(22):5019-22
9823301
Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8
9843981
Curr Biol. 1999 Mar 11;9(5):273-6
10074455
Int J Cancer. 1999 May 17;81(4):620-8
10225454
Cancer Res. 1999 Aug 1;59(15):3761-7
10446993
Oncogene. 1999 Aug 26;18(34):4808-18
10490814
Nucleic Acids Res. 2005 Jan 1;33(Database issue):D103-7
15608156
Cell. 2005 Jan 14;120(1):15-20
15652477
Genes Dev. 2005 Feb 15;19(4):489-501
15713842
Mol Pharmacol. 2005 Apr;67(4):1360-8
15662043
Nat Genet. 2005 May;37(5):495-500
15806104
Cancer Res. 2005 Jul 1;65(13):5588-98
15994931
Oncogene. 2005 Sep 8;24(40):6090-100
15940259
Int J Biochem Cell Biol. 2005 Dec;37(12):2437-56
16099193
Int J Cancer. 1999 Dec 10;83(6):809-14
10597200
Nat Genet. 2000 Mar;24(3):236-44
10700175
Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4291-6
10760295
Nat Genet. 2000 May;25(1):25-9
10802651
Oncogene. 2000 Apr 20;19(17):2165-70
10815808
Pac Symp Biocomput. 2000;:455-66
10902193
Biochim Biophys Acta. 2000 Jul 31;1471(1):M43-56
10967424
Nature. 2000 Nov 16;408(6810):307-10
11099028
Mol Pharmacol. 2001 Apr;59(4):657-63
11259608
Nucleic Acids Res. 2001 Apr 15;29(8):1791-800
11292852
Bioinformatics. 2001 Apr;17(4):369-70
11301307
Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21
11309499
Oncogene. 2001 May 3;20(20):2559-69
11420666
Oncogene. 2001 May 24;20(23):2982-6
11420711
Science. 2001 Oct 26;294(5543):862-4
11679672